Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments

Journal of Biological Chemistry

Volumn 287, Issue 29, 2012, Pages 24313-24319

  Jez, Jakub ^a   Antes, Bernhard ^b   Castilho, Alexandra ^a   Kainer, Manuela ^b   Wiederkum, Susanne ^b   Grass, Josephine ^a   Rüker, Florian ^a   Woisetschläger, Max ^b   Steinkellner, Herta ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b Babraham Research Campus   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITIES; ANTIGEN-BINDING SITES; CORE OLIGOSACCHARIDE; EXPRESSION SYSTEM; GLYCOFORMS; HUMAN CELLS; HUMAN TUMOR CELLS; IMMUNE RESPONSE; N-GLYCAN; N-GLYCANS; PRESENCE/ABSENCE; RECEPTOR BINDING; SIGNIFICANT IMPACTS; THERAPEUTIC APPLICATION; WILD TYPES;

BINDING SITES; BIOACTIVITY; ESTERIFICATION; GLYCOSYLATION; OLIGOSACCHARIDES; OPTIMIZATION; TUMORS; VACCINES;

ANTIBODIES;

ALPHA1,3 FUCOSE; BETA1,2 XYLOSE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FC RECEPTOR IIIA; FUCOSE; GALACTOSE; GLYCAN; IMMUNOGLOBULIN FC FRAGMENT; N GLYCAN; OLIGOSACCHARIDE; UNCLASSIFIED DRUG; XYLOSE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING SITE; BIOENGINEERING; BIOLOGICAL ACTIVITY; CHEMICAL MODIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; TUMOR CELL; WILD TYPE;

ANTIBODIES; CELL LINE, TUMOR; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLOW CYTOMETRY; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; POLYSACCHARIDES; RECEPTORS, IGG; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; TOBACCO;

EID: 84863806221     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.360701     Document Type: Article

References (30)

1. Reichert, J. M. (2008) Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 9, 423-430
2. Nelson, A. L., Dhimolea, E., and Reichert, J. M. (2010) Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9, 767-774
3. Wurch, T., Lowe, P., Caussanel, V., Bes, C., Beck, A., and Corvaia, N. (2008) Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy. Status on discovery research and clinical validation. Curr. Pharm. Biotechnol. 9, 502-509
4. Nelson, A. L., and Reichert, J. M. (2009) Development trends for therapeutic antibody fragments. Nat. Biotechnol. 27, 331-337
5. Wozniak-Knopp, G., Bartl, S., Bauer, A., Mostageer, M., Woisetschläger, M., Antes, B., Ettl, K., Kainer, M., Weberhofer, G., Wiederkum, S., Himmler, G., Mudde, G. C., and Rüker, F. (2010) Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng. Des. Sel. 23, 289-297
6. Jefferis, R. (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8, 226-234
7. Junttila, T. T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., Totpal, K., Kelley, R. F., and Sliwkowski, M. X. (2010) Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 70, 4481-4489
8. Yamamoto, K., Utsunomiya, A., Tobinai, K., Tsukasaki, K., Uike, N., Uozumi, K., Yamaguchi, K., Yamada, Y., Hanada, S., Tamura, K., Nakamura, S., Inagaki, H., Ohshima, K., Kiyoi, H., Ishida, T., Matsushima, K., Akinaga, S., Ogura, M., Tomonaga, M., and Ueda, R. (2010) Phase I study of KW- 0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28, 1591-1598
9. Ma, J. K., Barros, E., Bock, R., Christou, P., Dale, P. J., Dix, P. J., Fischer, R., Irwin, J., Mahoney, R., Pezzotti, M., Schillberg, S., Sparrow, P., Stoger, E., and Twyman, R. M. (2005) Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep. 6, 593-599 (Pubitemid 41122422)
10. Whaley, K. J., Hiatt, A., and Zeitlin, L. (2011) Emerging antibody products and Nicotiana manufacturing. Human Vaccines 7, 349-356
11. Lux, A., Nimmerjahn, F., Pulendran, B., Katsikis, P. D., and Schoenberger, S. P. (2011) Impact of differential glycosylation on IgG activity crossroads between innate and adaptive immunity III, in Crossroads between Innate and Adaptive Immunity III, pp. 113-124, Springer, New York
12. Marillonnet, S., Thoeringer, C., Kandzia, R., Klimyuk, V., and Gleba, Y. (2005) Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat. Biotechnol. 23, 718-723 (Pubitemid 41716362)
13. Castilho, A., Bohorova, N., Grass, J., Bohorov, O., Zeitlin, L., Whaley, K., Altmann, F., and Steinkellner, H. (2011) Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody. PLoS One 6, e26040
14. Strasser, R., Castilho, A., Stadlmann, J., Kunert, R., Quendler, H., Gattinger, P., Jez, J., Rademacher, T., Altmann, F., Mach, L., and Steinkellner, H. (2009) Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous β1,4-galactosylated N-glycan profile. J. Biol. Chem. 284, 20479-20485
15. Castilho, A., Strasser, R., Stadlmann, J., Grass, J., Jez, J., Gattinger, P., Kunert, R., Quendler, H., Pabst, M., Leonard, R., Altmann, F., and Steinkellner, H. (2010) In planta protein sialylation through overexpression of the respective mammalian pathway. J. Biol. Chem. 285, 15923-15930
16. Durocher, Y., Perret, S., and Kamen, A. (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9
17. Stadlmann, J., Pabst, M., Kolarich, D., Kunert, R., and Altmann, F. (2008) Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 8, 2858-2871
18. Radaev, S., Motyka, S., Fridman, W. H., Sautes-Fridman, C., and Sun, P. D. (2001) The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 276, 16469-16477
19. Strasser, R., Stadlmann, J., Schähs, M., Stiegler, G., Quendler, H., Mach, L., Glössl, J., Weterings, K., Pabst, M., and Steinkellner, H. (2008) Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 6, 392-402 (Pubitemid 351490228)
20. Forthal, D. N., Gach, J. S., Landucci, G., Jez, J., Strasser, R., Kunert, R., and Steinkellner, H. (2010) Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J. Immunol. 185, 6876-6882
21. Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., and Daëron, M. (2009) Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-3725
22. Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., and Umaña, P. (2006) The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281, 5032-5036 (Pubitemid 43847767)
23. Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H., and Presta, L. G. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody- dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740 (Pubitemid 34951677)
24. Bendandi, M., Marillonnet, S., Kandzia, R., Thieme, F., Nickstadt, A., Herz, S., Fröde, R., Inogés, S., Lòpez-Dìaz de Cerio, A., Soria, E., Villanueva, H., Vancanneyt, G., McCormick, A., Tusé, D., Lenz, J., Butler-Ransohoff, J. E., Klimyuk, V., and Gleba, Y. (2010) Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann. Oncol. 21, 2420-2427
25. Wozniak-Knopp, G., Stadlmann, J., and Rüker, F. (2012) Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds. PLoS One 7, e30083
26. Li, H., Sethuraman, N., Stadheim, T. A., Zha, D., Prinz, B., Ballew, N., Bobrowicz, P., Choi, B. K., Cook, W. J., Cukan, M., Houston-Cummings, N. R., Davidson, R., Gong, B., Hamilton, S. R., Hoopes, J. P., Jiang, Y., Kim, N., Mansfield, R., Nett, J. H., Rios, S., Strawbridge, R., Wildt, S., and Gerngross, T. U. (2006) Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24, 210-215 (Pubitemid 43221706)
27. Loos, A., Van Droogenbroeck, B., Hillmer, S., Grass, J., Kunert, R., Cao, J., Robinson, D. G., Depicker, A., and Steinkellner, H. (2011) Production of monoclonal antibodies with a controlled N-glycosylation pattern in seeds of Arabidopsis thaliana. Plant Biotechnol. J. 9, 179-192
28. Loos, A., Van Droogenbroeck, B., Hillmer, S., Grass, J., Pabst, M., Castilho, A., Kunert, R., Liang, M., Arcalis, E., Robinson, D. G., Depicker, A., and Steinkellner, H. (2011) Expression of antibody fragments with a controlled N-glycosylation pattern and induction of endoplasmic reticulum-derived vesicles in seeds of Arabidopsis. Plant Physiol. 155, 2036-2048
29. Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000) The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406, 267-273 (Pubitemid 30604397)
30. Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., Umaña, P., and Benz, J. (2011) Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U.S.A. 108, 12669-12674